Cardiovascular Outcomes Associated With Biologic Therapy in Inflammatory Dermatologic Diseases: A Systematic Review.

In contrast, in the 52-week randomized, double-blind, placebo-controlled CARIMA trial, although the authors found that psoriasis patients receiving secukinumab had increased flow-mediated dilation (FMD) vs placebo after 12 weeks, this difference did not reach statistical significance until repeat measurement at week 52, indicating that IL-17 blockade may have delayed cardiovascular protective effects [ 71 ].

also in 111,027 other papers